The treatment of keloids is constantly updated and developed. At the same time, the research on the treatment of keloids is also constantly being carried out. Not long ago, some scholars published a related literature about pirfenidone inhibiting keloids.  . Keloids are benign proliferative skin lesions that are difficult to treat and are a source of distress for patients. As far as its mechanism is concerned, recent literature shows that the conversion of keloid epidermis to dermis is one of its important pathogenesis. In the past, by studying the effect of the antifibrotic drug pirfenidone on keloid keratinocytes, it was found that pirfenidone has a certain inhibitory effect on keloids. In the experiment, keratinocytes isolated from normal skin tissue and scar tissue were cultured in vitro, and the effects of pirfenidone on cytotoxicity, cell migration, cell proliferation, and EMT-related genes and protein expression were studied. The experiment found that pirfenidone can significantly reduce the levels of vimentin and fibronectin in normal and keloid keratinocytes, and hinder the migration of basal cells. When the concentration of pirfenidone was from 200-1000ug/ml, the proliferation rate of cell basal cells showed a significant dose-dependent decrease. When the concentration of pirfenidone was as high as 1000ug/ml, the experiment did not find any cytotoxic effect . This study suggests that pirfenidone may inhibit the progress and recurrence of keloids. The literature shows that pirfenidone may have the prospect of treating keloids, but it is worth noting that the response of the same cells to the same drugs in vivo and in vitro is usually different. The most important thing is the effect of pirfenidone on cells in the body. The experimental results still need to be supported by clinical application data.